Longevity interventions temporally scale healthspan in Caenorhabditis elegans

Working Paper

Author(s):
Statzer, Cyrill; Reichert, Peter; Dual, Jürg (iD); Ewald, Collin (iD)

1   **Longevity interventions temporally scale healthspan in *Caenorhabditis elegans***

2   Cyril Statzer[1][§], Peter Reichert[2][§], Jürg Dual[2][*], and Collin Y. Ewald[1][*]

3

4   **1** Laboratory of Extracellular Matrix Regeneration, Institute of Translational Medicine,

5   Department of Health Sciences and Technology, ETH Zürich, Schwerzenbach CH-8603,

6   Switzerland

7   **2** Eidgenössische Technische Hochschule Zürich, Department of Mechanical and Process

8   Engineering, Institute for Mechanical Systems, Zürich CH-8092, Switzerland

9

10   § Authors contributed equally

11   *Corresponding authors: collin-ewald@ethz.ch (CYE) and dual@imes.mavt.ethz.ch (JD)

12

13   **Keywords:** acoustophoresis, microfluidics, healthy aging, maximum muscle strength,

14   healthspan, sickspan, aging biomarker, lifespan machine

15

16

Abstract

Longer lived individuals, such as centenarians or longevity mutants of model organisms, have later onsets and lower incidence rates of late-life morbidities or disabilities than the average population. However, whether increased lifespan is caused by a compression of the portion of life spent in a state of morbidity, i.e., "sickspan," is highly debated. It is unclear which health matrices are representative for measuring healthspan (time spent in good health); however, muscular performance is generally a good indicator for the health status in humans and a predictor for their mortality, regardless of the underlying cause. Here, we developed a novel microfluidic device that employs acoustophoretic force fields to quantify the maximum muscle strength and dynamic power in aging *C. elegans* populations. We found that longevity mutants have a delayed onset and lower declining rates in maximum muscle strength compared to wild type. Reconciling previous conflicting reports, we confirmed that certain longevity mutants exhibited a mild increase in relative sickspan measured by voluntary movement matrices, which is not the case when using our acoustophoretic force measurements, swim endurance, or other approaches. Using six different biomarkers for healthspan, we observed a time-dependent onset of morbidity, starting with a loss of stress resilience, a decline in dynamic power, and a decline in structural integrity, culminating finally in inactivity (lethargy) and a loss of mobility. We observed that a subset of aging biomarkers correlate with each other and maybe functionally interconnected. Surprisingly, we did not observe a compression of sickspan in longevity mutants but instead observed a temporal scaling of healthspan with diminishing returns for extreme lifespan extensions. Given the conservation of these longevity interventions, this raises the question of whether the healthspan of mammalian longevity interventions is temporally scaled as well.

41   **Introduction**

42   The continuously growing elderly population is projected to result in 1.5 billion people above

43   the age of 65 globally by 2050 [1]. This poses a significant challenge since old age is the major

44   risk factor for developing cancer, dementia, cardiovascular, and metabolic diseases [2], especially

45   since people suffer for approximately 20% of their lifespan from one or multiple of these

46   chronic illnesses, which are themselves accompanied by other late-life disabilities [2]. Current

47   estimates indicate that delaying the onset of these chronic diseases by two years would save

48   $7.1 trillion over the next fifty years in the US alone [3]. Therefore, major research efforts are

49   dedicated to understanding how to increase the time spent in good health (*i.e.*, healthspan) and

50   to postpone and compress the time spent suffering from age-related pathologies and chronic

51   diseases (*i.e.,* sickspan) [2,4–6].

52   People that are more than one hundred years old, so-called centenarians, display a

53   delayed onset and a lower incidence rate of late-life morbidities compared to people in the age

54   bracket of 80 to 89 years [7–12]. Genome-wide association studies have shown associations

55   between the exceptional longevity of centenarians and aging-related genes identified in model

56   organisms [2,13,14]. Mutations in genes that promote longevity in model organisms, such as *C.*

57   *elegans,* have been instrumental in identifying mechanisms that promote healthy aging [2,13–15].

58   A recent study has questioned this approach of using *C. elegans* longevity mutants to

59   gain insights for promoting healthy aging or mechanisms that prolong healthspan [16]. Using four

60   matrices (resilience to heat and oxidative stress, voluntary movement, and swimming

61   performance) to assess the "health" status of aging *C. elegans*, they found that four commonly

62   used longevity mutants outperformed wild type at any given timepoint at older ages, consistent

63   with previous reports. However, compared to their maximum lifespan, longevity mutants

64   displayed an increased sickspan-to-healthspan ratio compared to wild type [16]. Other studies

65   have not observed an increase of sickspan in long-lived *C. elegans* mutants, except in the case

66   of lower mobility or movement scores for the insulin/IGF-1 receptor longevity *daf-2(e1370)*

67   mutants [17–20]. A large part of the "prolonged sickspan" based on the motility of these *daf-*

68   *2(e1370)* mutants was attributed to behavioral preferences of food over exploration linked to

69   *odr-10* gene expression [17] or improper dauer-like quiescence behavior [20–24]. Although all these

70   studies showed that sickspan is not increased in longevity mutants, the question remained about

71   how healthspan changes when the lifespan is extended. We hypothesized that using other health

72   matrices independent of voluntary or behavioral influences, such as physical properties of

73   muscular strength, which is one of the best predictors for all-cause mortality in humans [25], we

74   might be able to quantify the health trajectory of *C. elegans* longevity mutants.

75   Here we confirm that voluntary movement during aging declines and this fragility is not

76   extended in longevity mutants, except mildly in *daf-2* mutants, using high-resolution lifespan

77   and movement measurements on plates. Instead of assessing swimming speed, we measured

78   swimming endurance and found *daf-2* longevity mutants outperforming wild type during aging.

79   We developed a novel microfluidic device and applied acoustophoretic force fields to quantify

80   the maximum force and power of *C. elegans*. Using a high frequency and high power acoustic

81   force field, it becomes possible to set up a contactless, constant in time, and uniform force field

82   acting along the whole *C. elegans* body. Therefore, this force field challenges swimming *C.*

83   *elegans* in a similar way body-weight exercises do for humans in a gravity field. Furthermore,

84   the acoustic field showed to be suited for stimulating a swimming response of resting *C.*

85   *elegans*. All longevity mutants showed delayed onset of the decline in maximum force and

86   dynamic power during aging. We observed heterogeneity between individuals across all

87   genotypes in the onset of age-related phenotypes, several correlated phenotypes, and a time-

88   dependent occurrence of multiple disabilities. However, we did not find a compression of

89   sickspan, but rather a temporal scaling of healthspan relative to their maximal lifespan across

90   genotypes.

91 **Results**

92 **Voluntary movement healthspan is proportionally increased by longevity interventions**

93 To obtain highly quantitative data on lifespan and healthspan, we used a lifespan machine [26].

94 Here, we defined the "voluntary movement healthspan" as the time spent fast crawling and the

95 "voluntary movement sickspan" as the time spent slow crawling or displaying minimal posture

96 changes (see Materials and Methods for detailed definition). We chose *eat-2(ad1116)* as a

97 genetic model for dietary restriction-mediated longevity, *glp-1(e2141)* as a genetic model for

98 germ-stem-cell-less-mediated longevity, *daf-2(e1368)* and *daf-2(e1370)* as genetic models for

99 reduced insulin/IGF-1 signaling mediated longevity. We cultured all animals at the same

100 temperature (15°C) and in the same environment with the same food source, except *glp-1* that

101 underwent a brief temperature upshift during development as in preparation for the lifespan

102 assay. To avoid dauer-specific traits that occur in reduced insulin/IGF-1 signaling mutants [22],

103 and to avoid pathogenicity from a bacterial food source [20], lifespans were run at 15°C on heat-

104 killed bacteria. Thus, the experimental setup was designed to offer optimal conditions and was

105 kept identical while *C. elegans* genotypes were varied.

106 As expected, we measured a significant increase in lifespan for these long-lived mutants

107 compared to wild type (Fig. 1a; Supplementary Table 1, Supplementary Video 1). Interestingly,

108 our data showed that the longer-lived the mutant was, the more prolonged was the voluntary

109 movement healthspan (Fig. 1b). Therefore, interventions that increase lifespan also increase the

110 time spent moving fast and actively.

111

112 **Relative increase for both health- and sickspan in long-lived mutants**

113 To better understand the rescaling of the time spent in frailty in these long-lived mutants, we

114 analyzed the fraction of slow-moving animals per day. We observed gaussian activity

115 distributions, which were shifted along the time axis for these longevity mutants (Fig. 1c). This

116 delayed onset of the sickspan (Fig. 1c) is consistent with the prolonged healthspan of these

5

117   long-lived mutants (Fig. 1b). However, except for dietary restricted *eat-2* mutants, the width

118   and the area of the Gaussian distributions were bigger for long-lived mutants than wild type

119   (Fig. 1c), suggesting an overall increase of sickspan. Thus, based on voluntary movement

120   tracking, long-lived mutants display increased absolute health- and absolute sickspan compared

121   to wild type. Next, we asked whether the fraction spent in health- and sickspan during the

122   lifespan is altered. Wild-type animals spent 78% of their lifespan fast-moving and 22% slow-

123   moving (Fig. 1d). For long-lived mutants, we recorded about 70-79% of their lifespan are spent

124   fast-moving (Fig. 1d, Extended Fig. 1), suggesting no compression of sickspan but rather a

125   proportional scaling of both health- and sickspan relative to their lifespan.

126

127   **Heterogeneity in the length of sickspan but a fixed onset of sickspan**

128   Since we did not observe a compression of voluntary movement sickspan of the entire

129   population, we wondered whether individual animals that outlived their siblings would display

130   a compressed sickspan. When we compared the sickspan traces of individual *C. elegans* for

131   each genotype, we were surprised to measure such a vast heterogeneity (Fig. 1d), given that all

132   these individual animals of a population are genetically identical, consume the same food, and

133   are housed in the same environment. Only the *glp-1*-mediated longevity showed an overall

134   compression of individual sickspan traces (Fig. 1d). For comparison among these different

135   genotypes, we decided to use "relative age" by dividing lifespan curves into quartiles and

136   computing the health-to-sickspan ratio for each quartile (Fig. 1d insets; Extended Data Fig. 2).

137   Consistent with previous reports on wild type [27], we found that in the first quantile of the

138   lifespan curve, individual animals spent about 90% of their lifetime fast-moving and 10% slow-

139   moving, indicating that these animals die young with a compressed sickspan compared to the

140   last quartile wherein animals spent about 75% of their lifetime fast-moving and 25% slow-

141   moving (Fig. 1d insets; Extended Data Fig. 1). Remarkably, it looks like the onset of an

142   individual's sickspan is a fixed event starting approximately when the first 10% of the isogenic

6

143 population starts to die (Fig. 1d). This observation suggests that up to a certain time point, the

144 animal's physiological integrity is maintained. After this time point, there appears to be a

145 stochastic decay resulting in a heterogenous sickspan distribution. Viewing the data using this

146 alternative interpretation of a fixed onset of sickspan would explain why animals in the first

147 quartile of the lifespan curve die young and spend less time in poor health, while animals in the

148 last quartile of the lifespan curve die old and spend more time in poor health. Thus, the time

149 spent fast- vs. slow-moving seems to have a fixed onset in time.

150

151 **Voluntary movement healthspan temporally scales with lifespan except in *daf-2* mutants**

152 The model of a fixed onset-timepoint for frailty would suggest that longevity interventions

153 would simply delay the onset. To address this, we contrasted the number of days spent fast-

154 moving (healthspan) for each individual as a function of their time lived (lifespan in days; Fig.

155 1e). We found that the time lived correlated and predicted the time spent fast-moving with an

156 R squared of 0.7 for wild type and R squared ranging from 0.5 to 0.8 for the longevity mutants

157 (Fig. 1e). Furthermore, the *glp-1* with an R squared of 0.8 and *daf-2(e1368)* with an R squared

158 of 0.5 indicate lower or higher heterogeneity, respectively, compared to wild type (Fig. 1e).

159 This is also apparent in the increased or decreased spread of data points below the regression

160 line in Fig. 1e and by increased or decreased lengths of the individual sickspan traces in Fig.

161 1d, respectively. One interesting aspect to note is that individuals in quartile 2 and 3, which

162 expire in the middle of the lifespan curves, displayed shortened healthspan relative to their

163 lifespan, whereas individuals in the last quartile showed an extended healthspan relative to their

164 lifespan (Fig. 1e). This might be because sicker individuals simply died earlier, leading to an

165 enrichment of healthier-aging individuals in the last quartile (Extended Data Fig. 1, 2). Based

166 on the high R squared values for all genotypes, we applied a linear model to investigate the

167 relationship between health- and lifespan (Fig. 1e). Steeper linear regression lines compared to

168 wild type would indicate an increase in health- to lifespan ratio. The slopes of the linear model

7

169   were steeper for *eat-2* and *glp-1*, but less steep for the two *daf-2* mutants compared to wild type

170   (Fig. 1e), suggesting that *glp-1* and *eat-2* spent a larger fraction and *daf-2* mutants spent a

171   smaller fraction of their lifespan actively moving. Since slopes of linear models can be sensitive

172   to extreme values, we compared the population means of health- and lifespan across all

173   genotypes (Fig. 1f). When we extrapolated the mean healthspan to mean lifespan ratio of wild

174   type, we found that *eat-2* and *glp-1* were close to this extrapolated line, whereas the *daf-2*

175   mutants lacked approximately three days (i.e., 7%) of mean healthspan in respect to their mean

176   relative lifespan (Fig. 1f). Thus, we uncovered that the prolonged voluntary movement

177   healthspan temporally scales with the prolonged lifespan for each of these longevity mutants

178   except less stringently for *daf-2* mutants.

179

180   **Exhaustion of Swimming endurance and stress resilience during aging**

181   Thus far, our observations and interpretations on healthspan are based on the decline of

182   voluntary movement on culturing plates in the abundance of food. Certain genotypes like *daf-*

183   *2(e1370)* are less motivated to forage and display a more rapid decline in voluntary foraging

184   behavior compared to wild type leading to the interpretation of being less healthy [17]. In our

185   setting, this lower foraging behavior is less pronounced in *daf-2(e1370)* since they were

186   cultured at 15°C, an environment that leads to less dauer program activation [22]. We used a

187   second approach to assess health based on voluntary movement and conducted a swimming

188   assay in the absence of food. Placing *C. elegans* in a water-based physiological buffer (M9

189   buffer) stimulates active trashing. When animals were young, they swim for more than 30 hours

190   without a decline in activity levels (Fig. 2). In the case of older animals, this endurance capacity

191   declines but less rapidly in longevity mutants (Fig. 2). Similarly, exposing aging animals to the

192   oxidative-stress-inducing agent arsenite, we report a progressive decline in stress resilience of

193   wild-type animals (Fig. 2). This decline in stress resilience is shifted to chronological older

194   animals in long-lived strains compared to wild type (Fig. 2). For both endurance swimming and

195   stress resilience, aging *daf-2* mutants surpassed chronological age-matched wild-type animals

196   (Fig. 2). Taken together, these results suggest that the observed deficit in healthspan of *daf-2*

197   mutants using a food-dependent movement assay might be largely due to their preferences in

198   lower foraging or exploratory behavior [17] rather than a loss of capability or frailty [16]. Moreover,

199   the progressive decline in endurance swimming and stress resilience during aging occurs

200   comparably in both wild type and longevity mutants but is delayed by just 1 or 2 days of

201   chronological age for longevity mutants (Fig. 2). This difference between two voluntary

202   movement assays led us to develop an inducible, motivation-independent exercise platform for

203   *C. elegans*. Our goal is to address the following shortcomings of current methods: the

204   movement should be inducible with a strong stimulus and not dependent on secondary cues like

205   food or intrinsic motivation to thrash, it should be measurable in a short time window to assess

206   health in this instant, and it should directly measure a physiologically relevant parameter like

207   maximum muscle force or functional tissue integrity. This is especially important when

208   comparing different genotypes, which often respond differently to their environment.

209

210   **Acoustophoretic characterization of *C. elegans* force and muscle power**

211   In humans, one of the best predictors for all-cause mortality is the decline in muscle maximum

212   force and power [25,28,29]. However, a tool or device to quantify the maximum force and power

213   of *C. elegans* muscles did not exist. The application potential would be immense since *C.*

214   *elegans* muscle structures are strongly conserved, as in mammals, and forced maximum

215   strength measurements to the point of collapse would be unethical in mammalian models. We

216   developed a microfluidic device harnessing the power of acoustic standing waves (Fig. 3a, 3b,

217   Supplementary Video 2, 3, Supplementary Methods). We have recently applied ultrasonic

218   waves to compress, move and quantitatively characterize larval *C. elegans* [30]. We reasoned that

219   we could employ ultrasonic standing waves to trap and stretch out *C. elegans* in the minima of

220   the acoustic force fields (Fig. 3c, 3d). *C. elegans* dislike being trapped and try to escape by

221   applying mechanical forces (body bending) against the acoustic force field (Fig. 3c, 3d). The

222   further away from the acoustic force field minimum, the harder it gets to move against the force

223   field (Fig. 3d). If the animal is stronger than the applied acoustic force field, then it can turn

224   around in the microfluidic chamber (Fig. 3c), typical escaping behavior of *C. elegans* known

225   as omega reversals [31]. Thus, the degree of deflection of the *C. elegans* body away from the

226   acoustic force field minimum provides an estimate of the maximal muscle strength the animal

227   can master to try to escape the acoustic trap.

228

229   **Muscular strength declines in aging *C. elegans***

230   To quantify muscular forces, we developed a model by dividing the *C. elegans* body plan into

231   13 rigid links connected by joints along the animal's midline (Fig. 3e). Upon applying acoustic

232   force fields, we measured the deflection of these 13 nodes for 30 seconds and the number of

233   times the animal escaped the force fields (Fig. 3f). A typical exercise round is structured in up

234   to ten cycles consisting of 30 seconds of ultrasonic force and a 5-second break (Fig. 3g). We

235   measured the muscular forces of aging wild-type *C. elegans* (Fig. 3g). After 3-5 cycles, we

236   observed muscle fatigue, which set in earlier the older the animals were (Fig. 3g). We observed

237   first an increase and then a decrease in the heterogeneity of individual *C. elegans* muscular

238   strengths (Fig. 3g). Similarly, we first saw an increase and then a progressive decline in muscle

239   power during aging (Fig. 3g). By contrast, we found that longevity mutants performed better in

240   terms of muscle strength and function at day 20 of adulthood (Fig. 3h). This indicates the

241   preservation of muscle power in aging longevity mutants.

242

243   **Longevity mutants showed prolonged healthspan assessed by the strength performance**

244   **in longitudinal comparison to wild type**

245   The overall force and power of a *C. elegans* depend on its muscle strength as well as its total

246   body size. In agreement with previous reports [32,33], we observed adult *C. elegans* kept growing

247 in body size beyond the reproductive period and then shrunk during aging (Fig. 4a, 4b). A

248 prolonged growing phase correlates with longevity [32]. We found that longevity mutants

249 prolonged their growing phase and shrunk less than wild-type animals during aging (Fig. 4a,

250 4b). Structural integrity declines during *C. elegans* aging, such as internal organ atrophy [34], loss

251 of internal pressure (Supplementary Method) [35], and disorganization of the exoskeleton cuticle

252 occurs [36]. We noticed that in the acoustic force field, *C. elegans* undergoes compression, and

253 this compressibility stays fairly constant during aging (Fig. 4d, 4e). We conclude that although

254 morphological changes occur during aging, the mechanical properties in regards to compression

255 are less affected by age. This points towards muscular strength playing a key role. On average,

256 young *C. elegans* can overcome the acoustic force field leading to an omega turn eight times

257 each cycle (Fig. 4e, Supplementary Video 4) . The ability to overcome the force field and turn

258 in the microfluidic chip progressively declines during aging but is preserved in longevity

259 mutants (Fig. 4e, Extended Data Fig. 3). Turning in the chip can be viewed as a measure of

260 high-intensity muscular capacity since the animal can completely overcome the force field. It

261 also showcases that the animal is not placid but trying to escape. Next, we assessed the overall

262 energy per individual *C. elegans* as an assessment of overall body volume deflected against the

263 force field. We found an increase of energy per individual until mid-age and then a decline (Fig.

264 4f) reminiscent of the longitudinal body size curve (Fig. 4a). In our measurements to determine

265 the overall force and power of *C. elegans*, the body size is a confounding factor. In all our

266 longitudinal measurements, we had included a positive control in the form of a muscle-

267 defective mutant (CB190) that carries a mutation in the muscle myosin class II heavy chain

268 (*unc-54*). These muscle-constriction-defective mutants were unable to perform omega turns in

269 the chip but showed similar compressibility and longitudinal growth curves, illustrating that the

270 rise and fall of the overall energy are confounded by the organismal growth curve. Therefore,

271 we decided to use the dynamic power as defined as energy expenditure relative to the previous

272 time point and normalized it by the volume of each animal (*i.e.,* volume; Fig. 4g). Using a

11

273   human analogy, total refers to how long a weight can be lifted, dynamic power only considers

274   the process of lifting the weight without holding the weight, and dynamic power takes the

275   weight of the person lifting the weight into account. In this way, we found that the overall force

276   and power of longevity mutants were preserved for almost three-quarters (55-83%) compared

277   to about one-third (30%) of their lifespan in wild type (Fig. 4g). Thus, muscular strength is

278   maintained longer in longevity mutants.

279

280   **Temporal scaling of age-related pathologies in longevity mutants**

281   Next, we asked whether other age-related pathologies or morphological changes show any

282   delayed onset on longevity mutants compared to wild type. We quantified 592 animals,

283   investigated timepoints between day 0 and day 33 (12 animals on average per strain and time

284   point) at the first two cycles of actuation (1183-time sequences), which comprised over 800'000

285   frames in total. We then manually quantified additional morphological changes such as intestine

286   length and diameter, pixel intensity, wrinkles in the cuticle, and pharynx diameter in a

287   subsampled representative subset (approx. 50'000 frames; Extended Data Fig. 4). Although not

288   all, many age-related phenotypes were delayed in their onset and displayed a slowed decline in

289   longevity mutants compared to wild type (Fig. 5, Extended Data Fig. 5). Rescaling phenotypic

290   trajectories of wild type by the lifespan extension observed in the long-lived strains revealed

291   that many closely match the trajectories observed in long-lived strains for both *daf-2* mutants

292   (Fig. 5C). Notably, for animals' length, diameter, volume, and intestine length, phenotypic

293   scaling was observed when comparing wild type to *daf-2(e1368)* and *daf-2(e1370)*. In the case

294   of *eat-2,* the observed lifespan extension was too limited to draw conclusions and *glp-1* never

295   ceased growing. The severely paralyzed myosin mutant *unc-54(e190)* displayed the opposite

296   phenotypic trajectories than all other genotypes (Fig. 5C). When approximating the phenotypic

297   trajectories as segmented linear fit reflecting the separated phases of growth and decline, we

12

298   observed that the starting values as young adults are often similar (Fig. 5D). However, the

299   slopes and point of decline are shifted compared to wild type.

300   Investigating each phenotype in isolation is hindered by the inherent noise in the measurement

301   as well as by the incomplete picture each phenotype provides. Furthermore, many phenotypes

302   like length, diameter, and volume were strongly correlated. For this reason, we subjected all

303   phenotypes to Principle Component Analysis (PCA) to study the overall age trajectory

304   (Extended Data Fig. 6A). We traced these phenotypes of all genotypes across the PCA plot as

305   they age (Extended Data Fig. 6B). All physiological parameters increased from young to

306   middle-aged and then revert again as the animal reached old age. However, muscle strength

307   density decreased steadily. Using the paralyzed mutant, we were able to establish the bottom

308   left quadrant as a reduced health area. This was only possible when using both physiological

309   and performance measurements and was entered only by the paralyzed strain as well as old

310   wild-type animals. The multi-phenotype traces are also shown for each genotype individually

311   (Extended Data Fig. 6C, 6D). Taken together, this suggested that many of these phenotypes

312   change similarly during aging, that many are temporally scaled in longevity interventions, and

313   that maximum muscle strength offers an orthogonal perspective on studying aging compared

314   to physiological features. This highlights the importance of performing high-intensity muscle

315   strength measurements when studying physiological aging and quantifying healthspan.

316

317   **Longevity mutants show prolonged absolute but not relative healthspan**

318   Our data revealed that longevity mutants stay healthier compared to wild type and experience

319   a slower decline in physiological integrity. Indeed, dividing the lifespan of each genotype into

320   three chronological fixed age categories: young (less than 7 days), middle (older than 8 but

321   younger than 19 days), and old age (>20 days of adulthood), showed a progressing decline of

322   volume-corrected work performed (Fig. 6a, 6b). Longevity mutants performed better in the

323   middle age group than wild type, but only *daf-2(e1368)* outperformed wild type in the old age

13

324   group (Fig. 6a, 6b). Using hierarchical clustering of temporally scaled phenotypes as a

325   complementary analysis, we found that longevity mutants often cluster with chronologically

326   younger wild-type samples (Extended Data Fig. 7).

327

328   **Integration of voluntary movement and forced maximum muscle strength quantification**

329   **to yield a comprehensive understanding of *C. elegans* healthspan**

330   Having two independent assessments of healthspan that act on very different stringency levels,

331   we can further divide *C. elegans* healthspan into 3 divisions: prime health (passes both

332   matrices), fragile health (passes 1 metric), and sickspan (failing both matrices) (Fig. 6c).

333   Consistent with previous observations in other species, the maximum power drops prior to the

334   cessation in general mobility [25,28,29]. Muscle performance is much more improved in longevity

335   mutants in relation to wild type compared to voluntary movement (Fig. 6c). Integrating both

336   matrices revealed that wild type spent around 16% of their lifespan in prime health, whereas

337   longevity mutants spent double the time in prime health (28-42%; Fig. 6c). From all four

338   longevity genotypes, *daf-2(e1368)* appears to be the healthiest strain (Fig. 6c). Thus, combining

339   multiple matrices of physiological and behavioral integrity is a powerful assessment of

340   healthspan.

341

342

Discussion

Understanding the relationship between healthspan and lifespan is an important question in aging research since geroscience aims to increase the time spent in good health and to postpone and compress the time suffering from age-related pathologies and chronic diseases [2,4,5,37]. Model organisms like *C. elegans* are used to identify longevity-promoting interventions that can then be of translational value for humans [13,15]. There is a fierce debate whether *C. elegans* longevity interventions show compression of sickspan and are of translational value for improving healthspan or healthy aging in humans [16–20]. In this study, we set out to develop a robust method to quantify maximum muscle strength as a highly interpretable healthspan metric with translational value. Lifespan measurements are well-established and allowed the study of hundreds of lifespan-extending compounds and genetic alterations, leading to ground-breaking discoveries. However, this development is not reflected in the area of healthspan extension. Numerous methods exist which often measure proxy phenotypes for healthspan that are also motivation dependent like pharyngeal pumping, thrashing, and others. With our approach, we were able to directly quantify muscle health in *C. elegans*. This is especially relevant since *C. elegans* is an ideal model system for large-scale genetic screening and both the microfluidic device as well as the image detection can be multiplexed. This approach could translate to the much-needed identification of (muscle) health-promoting interventions.

The microfluidic device operates using acoustophoresis to generate an acoustic force field to quantify the physical fitness and muscle strength of aging *C. elegans*. Using six different ways to assess healthspan in forms of voluntary movements, swimming endurance, stress resilience, muscular force, muscular fatigue, structural integrity/compressibility, and quantifying several age-related morphological changes, including cuticle/skin wrinkles, body, and internal organ sizes, we find that most of these phenotypic changes are postponed in longevity mutants. We observed a hierarchical and time-dependent succession in the occurrence of these phenotypes,

369 starting with a loss of stress resilience, then a loss of swimming endurance, decline in maximal

370 force as indicated by overcoming acoustic field (omega turns), decline in dynamic power,

371 seizing of body and organ growth (intestine), and then decline in voluntary movement and

372 becoming inactive and lethargic. Using principle component analysis, we show that many of

373 these phenotypes are strongly cross-correlated. The delay of all these age-related phenotypic

374 changes is evident when using chronological age as a reference point for comparison of

375 longevity mutants with wild type but disappears when using relative age as a reference. This

376 points to the idea of temporal scaling of the healthspan. Consistent with this idea, we find that

377 sickspan is neither compressed nor prolonged in longevity mutants compared to wild type.

378 Thus, our quantifications suggest that *C. elegans* healthspan undergoes temporal scaling in

379 longevity.

380 Aging is defined as a set of phenotypes or senescent pathologies occurring with a higher

381 proportion in older individuals [38]. Which senescent pathologies limit the lifespan depends on

382 the context and are different for different species, genotypes, and environments [38,39]. Whether

383 our chosen set of phenotypes assessed are directly limiting or affecting lifespan is unclear.

384 However, it is evident that not one single mechanism underlies all our measured age-related

385 phenotypes. On the other extreme, we do not observe a "one mechanism causing one age-

386 related pathology" mechanism. Our data shows that some phenotypes correlate and also follow

387 a hierarchal time-dependent order of occurrence, indicating that these senescent pathologies are

388 interconnected. This favors a mixed model of several causal mechanisms affecting multiple

389 connected and independent senescent pathologies/phenotypes, including lifespan limiting

390 phenotypes [38,39]. Even if we might not measure lifespan limiting phenotypes directly, the

391 interconnectedness of phenotypes should reveal the same picture of temporal scaling of age-

392 related pathologies.

393 The lifespan of *C. elegans* can be increased by up to ten-fold [40] and decreased by 40-

394 fold, but surprisingly the lifespan curves often follow the same rescaled distribution [41].

16

395   Temporal scaling was also noted when comparing expression profiles of longevity mutants

396   compared to wild-type *C. elegans* [42]. Aging is thought to be caused by the accumulation of

397   damage [14,43]. Organisms either remove, detoxify, compartmentalize, or dilute molecular

398   damage [43]. In dividing stem cells, yeast, or bacteria, damaged macromolecules or organelles

399   are kept in the "mother" cell leading to accumulation of damage [14,44,45]. Since *C. elegans*

400   somatic cells are post-mitotic, the main driver of aging dictating the lifespan of *C. elegans*

401   might be the accumulation of damage in non-dividing cells. In a perfect life-conditioned

402   environment such as the laboratory setting, free from ever-changing environmental fluctuations

403   or pathogens, the only lifespan limiting factor probably boils down to the imperfectness of

404   biological systems [43], leading to accumulation of damage, stochastic decay of homeostatic

405   mechanisms [14], and consequently to age-related pathologies and phenotypes. In light of this, it

406   might be less surprising that the onset of pathologies is strongly linked to lifespan and thereby,

407   healthspan is rather temporally scaled than prolonged in longevity.

408   Whether temporal scaling also occurs in mammalian longevity needs to be determined

409   in the future. However, certain longitudinal *C. elegans* phenotypes are comparable to human

410   age-related phenotypes. Analogous to the *C. elegans* volume increase to peak mid-age and then

411   decrease is that human BMI and waist circumference also follows this early-to-mid-life increase

412   reaching a peak around 65-70 years and then declining [46]. Furthermore, grip strength

413   progressively declines after the age of 30-40 [46], similarly to *C. elegans* muscular strength. This

414   raises the question of whether non-compression of sickspan observed in *C. elegans* means or

415   interpolates to non-compression of sickspan in humans? Since aging is universal, it is tempting

416   to speculate that the underlying mechanisms of aging or age-dependent phenotypes are also

417   universal. This might be a potentially erroneous or unproven extension of the observation that

418   almost all living things age [38]. Although phenotypic changes, such as the loss of *C. elegans*

419   muscle force, is analogous to loss of grip strength or muscle strength loss in humans, the

420   underlying biological mechanisms resulting in physical weakness might be different. Our study

421   makes no conclusion or interpolation about the compression of the sickspan in humans.

422   There is an accumulating body of evidence that long-lived humans are healthy during

423   old age. For instance, 56-83% and 15-23% of centenarians, people over the age of hundred

424   years, delay the onset of chronic age-dependent diseases and physical disabilities or were even

425   free of such co-morbidities and frailties, respectively [7,10]. Centenarians have lower incidence

426   rates of chronic illnesses compared to their 90- or 80-year old matched-controls [8,9,11,12]. This

427   also extends to family members related to centenarians compared to families without

428   centenarians [47,48]. Thus, centenarians have a later onset and a lower rate of incidence compared

429   to people in their eighties, similar to our observation when comparing longevity mutants to

430   wild-type *C. elegans*. However, since centenarians get to enjoy at least 20 more years, how

431   would this comparison look if we were to compare relative age to chronological age? Is

432   sickspan compressed or temporally scaled in centenarians compared to the average population?

433   As our life expectancy doubled in the last hundred years and we are on the course of potentially

434   reaching the limit of our lifespan [37], the accompanied delayed onset of disabilities already

435   started to decelerate in longer-lived woman compared to men [49]. On the other hand, there are

436   several interventions that increase healthspan without increasing lifespan per se identified in

437   mice [50,51] and Rhesus monkeys [52]. Thus, studying longevity is an important first step of

438   identifying molecular mechanisms promoting healthy aging, but our study and others [50–52] point

439   toward that it is crucially important for geroscience to start investigating interventions that

440   improve healthspan directly in future studies [6]. Initial steps in defining healthspan [4,5] and also

441   tools and experimental setups, including this study, are being developed to reliably quantify

442   healthspan [53–57].

443   In summary, we have demonstrated that *C. elegans* sickspan is neither compressed nor extended

444   in longevity mutants providing an alternative answer to an ongoing debate in the aging field.

445   With our measurements, we showed that previous claims that insulin/IGF-1 receptor mutants

446   have increased sickspan compared to wild type are correct if the voluntary movement is

447   measured, but not the case if the muscular function or other healthspan measurements are

448   considered that do not rely on the behavioral state of the animal. By adjusting the reference

449   system from chronological age to relative age, we provide evidence that the healthspan of

450   longevity mutants undergoes temporal scaling. Future studies using our acoustophoresis

451   approach to study the role of healthspan will reveal novel strategies to improve healthy aging.

452

453

454   **Author contributions**

455   All authors participated in analyzing and interpreting the data and designing the experiments.

456   CS performed lifespan assays. CYE and CS performed swimming and oxidative stress assays.

457   PR designed and performed microfluidic assays. CS and PR analyzed the datasets jointly. CS

458   and CYE wrote the manuscript in consultation with the other authors.

459

460   **Author Information**

461   The authors have no competing interests to declare. Correspondence should be addressed to C.

462   Y. E. and J.D.

463

464   **Acknowledgment**

469

Figure 1: Voluntary movement quantification in aging C. elegans populations. *C. elegans lifespan analysis displaying survival (A), healthspan (B), and sickspan (C) for each genotype. Error bars display the standard error between plates at 24h intervals. Healthspan refers to the timespan of fast movement, sickspan to the time spend in sedentary movement, and lifespan to the time until the animal fails to move irretrievably. The fate of each individual is displayed separately for each genotype overlayed with the population's survival (D). Here, each individual's healthspan is marked as a transparent line spanning from young adulthood to the onset of sickspan marked by a black dot and then extends further as sickspan until the individual's point of death on the population survival curve. The inset displays the overall proportion each genotype spends in their healthspan for each lifespan quantile ($Q_1 - Q_4$). The correlation between health and lifespan is shown in figure (E). Each individual is represented as a point with its lifespan on the x-axis and its corresponding healthspan on the y-axis. A linear model passing through the origin is shown as a solid line. The N2 model is superimposed on the longevity mutants as a red and white dashed line. All genotypes are compared to temporarily scaled N2 with the mean population life- and healthspan and error bars indicating the standard errors (F). The extrapolated ratio of health- to the lifespan of wild type*

483 *(0.78) is displayed as a dashed black line. The distance of each population average is marked by a vertical line, and the*
484 *difference in expected healthspan is indicated.*

485

486

487

488 ***Extended Data Fig. 1: Paradoxon - young animals die apparently in good health.***
489 *The sickspan distribution for every quartile of the lifespan distribution is displayed as boxplots with each strain in a separate*

490   *panel (A). Animals experience progressively higher sickspan ratios with each quantile, with the two middle quantiles being*
491   *the most similar. The distributions of the first and fourth quartile are shown as violin plots with their median line highlighted*
492   *by a horizontal segment showcasing the increase of relative sickspan and heterogeneity with age across genotypes (B). To*
493   *compare the individual genotypes for each relative age cohort, the corresponding quartiles are contrasted as boxplots for*
494   *each strain and each quartile in a separate panel and indicate temporal scaling of healthspan (C). The sickspan ratio is*
495   *compared across genotypes and quartiles (Mann-Whitney test) and the P-values are depicted as symbols (ns > 0.05, * <*
496   *0.05, ** < 0.01, *** < 0.001, **** <0.0001). When all quartiles are displayed, the median sickspan percentage of the first*
497   *and last quartile of the wild type population are indicated as dashed horizontal lines. The number of observations associated*
498   *with every subpopulation is displayed at the bottom of each observation. Each strain is shown in its distinct color, and*
499   *increasing age is reflected by increasingly dark coloring.*

500

501

502

Extended Data Fig. 2: Relative healthspan within early and late dying C. elegans groups.

*To address the question whether outliers drive the overall health-to-lifespan ratio, each genotype was divided into seven groups with equally sized age bins between the first and last recorded death in each genotype's population to visualize the distribution of death events. At the top of each bar, the number of animals observed to die in this cohort and its share in the overall population is displayed (**A**). The healthspan distribution in each age group is shown as a violin plot (**B**). The average percentage of each population spent in their healthspan is displayed above each group, with the population size indicated in brackets. The health-to-lifespan diagonal is shown as a dashed line, and a loess trendline was fitted to the binned datasets with a 95% confidence interval shaded in grey. In case the sample size falls below a threshold, the violin plot was omitted. Each analysis is displayed separately for every C. elegans genotype, which are each shown in a separate line and in a distinct color. The spread of the healthspan distribution increases at older ages, with some animals experiencing nearly no sickspan and others spending most of their life in the sickspan portion.*

514

Figure 2: Progressive movement decline with age in unchallenged swimming assay and when exposed to arsenite.
In all panels, the time after subjecting the C. elegans populations to the arsenite stress is displayed on the x-axis and the movement activity of animals on the y-axis. The animal age at the start of the experiment is shown at the right of every panel. The mean activity in 14 mM arsenite is shown as a continuous line and in M9 as dashed lines. M9 was selected to avoid issues related to osmolarity. Vertical lines reflect the standard deviation at every measurement point. Two daf-2 alleles and N2 populations were maintained at 15°C and subjected to movement quantification at three aging time points (a). The daf-2(e1370) allele was also assayed in a spe-9 background and therefore maintained at 15°C until L3 and then shifted to 25°C until the start of the assay (b). The glp-1(e2141) strain was compared against a spe-9 population and maintained at 25°C after population lysis until the time of measurement.

25

Figure 3: Experimental setup to measure maximum C. elegans muscle strength:
Top view of the schematic representation of the silicon/glass acoustofluidic chip, fluid in- and outlets, and the piezoelectric transducer positioned at the bottom and C. elegans trapped in the standing wave (A). A photograph of the back of the chip together with the metal clamps, the attached fluid connectors, temperature probe, and a piezoelectric transducer is shown (B, top). The front view of the chip provides an overview of the device shape, the microfluidic channel, and the measurement region (MR) (B, bottom). A day 4 wild type C. elegans, as seen by the camera in the measurement region, is displayed together with the image processing output highlighting the outline and the segmented midline of the animal as well as the channel borders and centerline (C). The effect of the acoustic field (frequency: 3.543 MHz, voltage amplitude: 76 Vpp, $\lambda/2$ mode) is shown in (C, 2), aligning the animal at the midline. The animal exercises maximum muscle power attempting to bend its head away from the midline (C, 3) to achieve a turn (C, 4), likely as an attempted escape response. The working model to quantify the C. elegans muscular force consists of 13 rigid links along the animal's midline, which are connected by joints. Blue arrows reflect the muscle activity acting on each joint to generate a force against the acoustic field (E). The acoustic force acting along the animal's body is modeled as the individual acoustic forces acting on the grey spheres aligned along the body and represented by black arrows, with the length of each arrow being proportional to its force or moment magnitude. The acoustic radiation potential is illustrated using a C. elegans cross-section highlighting the animal's four body wall muscles (D). If stretched, the animal rests at the minimum (see C 2) and, upon muscle contraction, moves upwards in its potential energy well (see C3). The four C. elegans frames (C 1-4) are put in the context of one 30 seconds actuation cycle showing the time-resolved total energy and mechanical work quantification for this animal (F). Red areas reflect regions of zero energy due to the acoustic field being turned off, and the blue areas indicate C. elegans turn movements during which muscle force estimation is paused. A C. elegans maximum force assessment routine consists of multiple 30 seconds exercise rounds intermitted by 5-second breaks for a total of up to ten actuation cycles. For wild type, this exercise regimen is displayed with the exercise rounds on the x-axis, the total power (time-averaged) on the y axis, as derived from the respective total energy curve in (F), and the age of the population given at the top of each facet (G). Wild type C. elegans is contrasted to long-lived C. elegans genotypes across up to ten exercise rounds focusing on the aged cohort above day 20 of adulthood (H).

26

552

N2 vs. daf−2(e1368)

553

554
555 *Figure 4: Time course of fitness- and structural-related phenotypes for wild type and long-lived C. elegans under acoustic*
556 *stimulation.*
557 *Acoustic compression was used to quantify phenotypes directly (# turns, energy, diameter- and volume compression, and*
558 *dynamic power by volume) as well as indirectly by exploiting the non-destructive linear alignment of the animals (length,*
559 *volume). Randomly selected images for N2 (A) and daf-2(e1368) (B) at different ages are displayed to illustrate the*
560 *positioning of the C. elegans in the microfluidic measurement channel and how all matrices are shown below were obtained.*
561 *Measurements are displayed as mean ± standard error for each assessed age point and subjected to local polynomial*
562 *regression fitting displayed as a full line with the confidence interval set to 95% and bounded by dashed lines. For the*
563 *acoustic compression only, the fitted line is shown. The length (C) and volume (D) of the animal was quantified automatically*

27

564 *using the entire length and area of the animal in the channel, respectively. The number of turns was quantified manually and*
565 *corresponded to the number of times an animal successfully changed its orientation in the channel by 180°. The total energy*
566 *of the individual was calculated using the magnitude of the lateral deflection of the animal from the channel middle (F). The*
567 *compression experienced by the animal diameter (G) and volume (H) when the field is activated was computed automatically*
568 *and displayed as a full line when the field is on and a dashed line when the field is off. The dynamic power/volume (I) reflects*
569 *the work the animal performs against the field to change its lateral position in the channel and is normalized by the overall*
570 *volume of the animal to enable comparisons across genotypes making this the most informative health parameter. The mean*
571 *value for day 0 and day 33 N2 animals are indicated in black dashed lines, and the half-activity value between these two*
572 *extremes is shown as a full line which is also used to deduce the health- to sickspan transition for each genotype. Using this*
573 *N2 half-activity value, the individual strains reach their sickspan at approximately 10 days for N2, 28 days for daf-2(e1368),*
574 *20 days for daf-2(e1370), 18 days for eat-2, and 27 days for glp-1 while CB190 spends its entire lifespan in its sickspan*
575 *fraction. Long-lived genotypes, in general, do not experience the same linear energy density decline as wild type since their*
576 *total energy decrease is slowed down, as is their growth leading to a non-linear energy density trajectory.*

577
578
579
580

Extended Data Fig. 3. C. elegans movement in the acoustic exercise chamber.

The exercise regimen was benchmarked for wild type (N2) C. elegans at different ages to quantify after how many cycles they experience muscle fatigue (A, B). Every trace corresponds to one individual animal that was up to ten times subjected to 30 seconds maximum force exercise followed by a 5 seconds break (A). Thicker lines represent the population means at every time point. To quantify maximum muscle strength, we selected the first two actuation cycles (B) at which no fatigue can yet be identified. The total energy is computed over the entire body and muscle apparatus of the animal. Interestingly, the spline position most activated in this exercise is the head and tail sections (C). Focusing on the head we quantified the relative head movement for different strains at old age and also observed the same trend of decreasing movement with higher actuation cycles (D). The extreme case of the paralyzed CB190 vs. N2 in young adulthood displays that while the mutant is still able to move the head away from the midline of the field when the acoustic field is off, it is unable to move when the field is on while N2 successfully fights against the applied forces (E).

593

Figure 5.Temporal scaling of C. elegans aging phenotypes.

The measured values of selected phenotypes are shown using different scales on the y-axis, animal age on the x-axis, and facetted by strain (A). To address the temporal scaling of phenotypes hypothesis, the loess fit of the measured values for wild type is shown as a solid grey line, and it is temporally scaled values using the respective mean lifespan increase experienced by the respective strain are shown as a dashed line also in grey. The measured phenotype trajectory for each strain is shown in color, each in a separate panel. The maximum fitted value is marked using. White point and its increase relative to the maximum fitted values measured for wild type are shown for both the age and phenotype variables. The same phenotypes as in subfigure (C) are modeled using a piecewise linear relationship in (B). The breakpoint of the segmented fit is estimated by the model at the age value where the linear relationship between the measured phenotype and population age changes. The individual animals measured at each time point are displayed as mean +/- standard error.

608

609
610 *Extended Data Fig. 4. Phenotypes quantified within the microfluidic setup:*
611 *Automated quantification of C. elegans diameter (D = diameter) evaluated at the middle segments colored in red and the*
612 *length (L = length) of the animal along its spine colored in light blue (A), The change in diameter and length quantification*
613 *as the field is switched (US = ultrasound) is indicated. The assumptions and necessary simplifications that were made to*
614 *analyze the acquired frames are listed (B). Excerpts of the manual quantification of C. elegans intestine length and diameter,*
615 *pharynx width and height, and the number of cuticle wrinkles are displayed (C). Annotation was performed in a self-*
616 *developed image annotator suite based on the python programming language. Principal component analysis (PCA) of the*

31

617   *measured phenotypes are displayed for aging wild type (N2) C. elegans individuals, with each point representing one*
618   *individual. The overlaying components refer to the highly correlated features length, volume, and diameter. Tissue*
619   *heterogeneity and age pigments were studied by analyzing the intensity distribution across different cross-sections along the*
620   *animal's fitted spine. Representative images of tissue and cuticle weakening displaying an increased bending angle of older*
621   *animals compared to younger individuals as they attempt to turn in the channel (F). Similarly, older animals are smaller and*
622   *sometimes display cuticle wrinkles (G). The strong stimulation of the acoustic force in the animals is shown for a*
623   *representative daf-2(e1368) animal (H). The spline midline and head position is displayed for seconds preceding (left), and*
624   *after (right), the acoustic field is activated. The animal directly responds with a strong escape response.*

625

626

Extended Data Fig. 5: Rationale behind the partitioning of physical properties into scaled and unscaled phenotypes.
Phenotypes displaying an age-dependent change and at least a partial temporal shift for any long-lived strain were manually classified as temporally scaled phenotypes (A, B), and phenotypes that do not satisfy these conditions are categorized as unscaled phenotypes (C, D). The quantified phenotypes are fitted using a loess model in all panels. The observed values for each individual are displayed using mean +/- standard error for each timepoint (A, C). The maximum value predicted by the loess fit is shown, and the increase relative to the wild type maximum is displayed at the top of the graph.

Extended Data Fig. 6: Principal component analysis of temporally scaled phenotypes to identify similarity between phenotypes and their contributions.

The subset of temporally scaled phenotypes for each individual was subjected to principal component analysis, and the first two principle components are shown together with the variance they explain. The contribution of each phenotype to the two first principle components is displayed as vectors with the orientation reflecting the directionality and the color and length capturing the contribution of each phenotype (A). The overall progression of young to middle-aged to old individuals through the phenotype landscape is schematically illustrated. The bottom left quadrant is highlighted in red to indicate its association with animals experience a poor health status. To compare the effect of age on the clustering of the different C. elegans genotypes all animals were grouped into 3 age categories, and the individual genotypes were shown in different

34

646   *colors (B). Confidence ellipses are drawn at the level of 95% for all samples (transparent) and the sample means (non-*
647   *transparent). To compare the effect of age separately for each genotype, the three age categories are shown for each strain,*
648   *young in green, middle-aged in yellow and old animals in red (C). Complete separation of age and genotype is provided in*
649   *panel (D), highlighting the measurements for every individual animal encompassed by the 95% sample confidence ellipse.*

650

651
652

35

653
654 ***Extended Data Fig.7: Hierarchical clustering of temporally scaled phenotypes.***
655 *The similarity between sampled genotypes and ages are displayed using hierarchical clustering. The comparison between all*
656 *samples (A), between each long-lived genotype and wild type (B, D, F, H), and within each long-lived is shown (C, E, G, I).*
657 *The tree is cut in five clusters when comparing all samples and in all other cases in four clusters and colored from left to*
658 *right.*
659

660
661

662
663

664
665 **Figure 6 Integration of voluntary movement and forced maximum muscle strength quantification to yield a**
666 **comprehensive understanding of C. elegans healthspan.**
667 *The volume-corrected relative work performed by each genotype and grouped by age category (young <= 7 days, 8 < middle*
668 *< 20 days, old >= 20 days) is shown as boxplots facetted by genotype (A) and by age category (B). P-values of selected*
669 *comparisons (Mann-Whitney test) are displayed as symbols (ns > 0.05, * < 0.05, ** < 0.01, *** < 0.001, **** <0.0001).*
670 *The Population medians for young and old N2 are displayed as horizontal dashed lines across all panels.*
671 *C) The measured lifespan of each C. elegans genotype is displayed with animal age on the x-axis, the fraction of the*
672 *population that is alive on the y-axis, and the mean and standard error between plates shown as point and line range. The*
673 *voluntary movement was quantified using the active vs sedentary behavior of the unstimulated animals on plates and is*
674 *shown for each population as a bar at the top of each panel. Muscle health and the corresponding onset of sickspan due to*
675 *reduced muscle function is depicted as a bar at the bottom of each facet. The position on the lifespan curve corresponding to*
676 *the health-to-sickspan transition of either the unstimulated or stimulated healthspan quantification is marked by a white*
677 *circle. The two health assessments divide the lifespan curve into three segments with decreasing health status reflected by*
678 *increasing transparency.*

679
680
681
682
683
684
685
686
687
688
689
690
691
692

Materials and Methods

Strains

Caenorhabditis elegans strains were maintained on NGM plates and OP50 *Escherichia coli* bacteria. The wild-type strain was N2 Bristol. Mutant strains used are described at www.wormbase.org: LGII: *eat-2(ad1116)*; LGIII: *daf-2(e1368, e1370), glp-1(e2141)*.

C. elegans **culturing conditions**

C. elegans populations were age-synchronized by isolating eggs from gravid C. elegans adults, incubating them for 18 hours in M9 until hatching in the presence of 5 µg mL−1 cholesterol (Sigma-Aldrich). Hatched L1-larvae were grown on standard culturing NGM OP50 plates and then shifted to 50 mM FUDR plates seeded with heat-killed OP50 plates when reaching the L4 state. Animals were maintained on FUDR plates until the measurement of different ages was taken. The *glp-1* genotype was placed at 25°C after bleach treatment and shifted back to 15°C at the L4 stage and otherwise treated equally to the other strains. Except for *glp-1* during its development, all animals were always maintained and aged at 15°C.

Automated survival assays using the lifespan machine

To compare the lifespans among wild type and long-lived mutants, we raised all animals for several generations in parallel. Automated survival analysis was conducted using the lifespan machine setup described by [26]. Briefly, approximately 1000 L4 animals were resuspended in M9 and transferred to NGM plates containing 50 µM 5-Fluoro-2'deoxyuridine (FUdR) seeded with heat-killed OP50 bacteria and incubated at 15°C until day 4 of adulthood. Animals were then resuspended in M9 and transferred to fresh FUDR plates containing tight-fitting lids (BD Falcon Petri Dishes, 50x9mm), and the plates were dried with their lids open for 30 minutes after transfer. The plates were incubated for five additional days to rule out contamination and then loaded in the lifespan machine. Air-cooled Epson V800 scanners were utilized for all

719   experiments operating at a scanning frequency of one scan of 30 minutes. Temperature probes

720   (Thermoworks, Utah, US) were used to monitor the temperature on the scanner flatbed and kept

721   constant at 15°C.

722

723   **Voluntary movement healthspan measured by lifespan machine**

724   The time point at which the animal stops moving completely and irretrievably is classified as

725   the point of death and defines the lifespan of each individual. The health- to sickspan transition

726   is estimated by the time point when major movement ceases and exclusively head movements,

727   posture change, and minor body movements can be observed. The animal is also required to be

728   sedentary and remains in the rough vicinity of the area; it will ultimately die.

729

730   **Microfluidics device measuring muscle strength**

731   The detailed description of the microfluidics device development and characterization is found

732   in the Supplementary Methods file.

733

734   **Oxidative stress assay arsenite with automated wormtracker**

735   Voluntary movement in liquid, as well as resistance to oxidative stress, was quantified using

736   the wMicroTracker (NemaMetrix) platform. Briefly, animals were resuspended in M9 at

737   indicated time points and washed three times with M9 by centrifugation. 30 – 40 *C. elegans*

738   were pipetted into each well of a round-bottomed 96- well plate in either M9 or 14 mM

739   sodium arsenite solution and assayed for 50 hours. Each genotype was always measured both

740   in M9 as well as arsenite in parallel to enable comparisons. Activity measurements were

741   analyzed using the R programming language, and average activity, as well as the standard

742   deviation of wells, are shown.

743

744   **Figure generation and statistics**

745   The analysis was performed using the statistical software R. data processing and visualization

746   was performed using the tidyverse package collection, most prominently dplyr and ggplot2.

747   Furthermore, packages were used for lifespan analysis (survival, survminer), computing and

748   visualizing PCA (stats and ggfortify, factoextra), fitting loess models (stats), and segmented fits

749   (segmented), labeling (ggrepel) comparing distributions (ggpubr) and arranging figures

750   (cowplot).

751

752

References

1. Nations, D. of E. and S. A. P. D. U. World Population Ageing 2019: Highlights. 1–46 (2019).

2. Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of ageing. *Nature* **561**, 45–56 (2018).

3. Goldman, D. P. *et al.* Substantial health and economic returns from delayed aging may warrant a new focus for medical research. *Health affairs (Project Hope)* **32**, 1698–1705 (2013).

4. Kaeberlein, M. Translational geroscience: A new paradigm for 21st century medicine. *Translational Medicine of Aging* **1**, 1–4 (2017).

5. Kennedy, B. K. *et al.* Geroscience: linking aging to chronic disease. *Cell* **159**, 709–713 (2014).

6. Olshansky, S. J. From Lifespan to Healthspan. *JAMA : the journal of the American Medical Association* **320**, 1323–1324 (2018).

7. Ailshire, J. A., Beltrán-Sánchez, H. & Crimmins, E. M. Becoming centenarians: disease and functioning trajectories of older US Adults as they survive to 100. *The journals of gerontology Series A, Biological sciences and medical sciences* **70**, 193–201 (2015).

8. Andersen, S. L., Sebastiani, P., Dworkis, D. A., Feldman, L. & Perls, T. T. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. *The journals of gerontology Series A, Biological sciences and medical sciences* **67**, 395–405 (2012).

9. Evans, C. J. *et al.* Place and cause of death in centenarians: a population-based observational study in England, 2001 to 2010. *PLoS medicine* **11**, e1001653 (2014).

10. Evert, J., Lawler, E., Bogan, H. & Perls, T. Morbidity profiles of centenarians: survivors, delayers, and escapers. *The Journals of Gerontology: Series A* **58**, 232–237 (2003).

11. Ismail, K. *et al.* Compression of Morbidity Is Observed Across Cohorts with Exceptional Longevity. *Journal of the American Geriatrics Society* **64**, 1583–1591 (2016).

12. Kheirbek, R. E. *et al.* Characteristics and Incidence of Chronic Illness in Community-Dwelling Predominantly Male U.S. Veteran Centenarians. *Journal of the American Geriatrics Society* **65**, 2100–2106 (2017).

13. Kenyon, C. J. The genetics of ageing. *Nature* **464**, 504–512 (2010).

14. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).

788   15. Magalhães, J. P. de, Stevens, M. & Thornton, D. The Business of Anti-Aging Science.
789   *Trends in Biotechnology* **35**, 1062–1073 (2017).

790   16. Bansal, A., Zhu, L. J., Yen, K. & Tissenbaum, H. A. Uncoupling lifespan and healthspan
791   in Caenorhabditis elegans longevity mutants. *Proceedings of the National Academy of*
792   *Sciences* **112**, E277-86 (2015).

793   17. Hahm, J.-H. *et al.* C. elegans maximum velocity correlates with healthspan and is
794   maintained in worms with an insulin receptor mutation. *Nature communications* **6**, 8919
795   (2015).

796   18. Huang, C., Xiong, C. & Kornfeld, K. Measurements of age-related changes of
797   physiological processes that predict lifespan of Caenorhabditis elegans. *Proceedings of the*
798   *National Academy of Sciences of the United States of America* **101**, 8084–8089 (2004).

799   19. Stamper, B. L. N. *et al.* Movement decline across lifespan of Caenorhabditis elegans
800   mutants in the insulin/insulin-like signaling pathway. *Aging cell* **17**, e12704 (2018).

801   20. Podshivalova, K. & Kerr, R. A. How a Mutation that Slows Aging Can Also
802   Disproportionately Extend End-of-Life Decrepitude. *Cell reports* **19**, 441–450 (2017).

803   21. Ewald, C. Y., Landis, J. N., Abate, J. P., Murphy, C. T. & Blackwell, T. K. Dauer-
804   independent insulin/IGF-1-signalling implicates collagen remodelling in longevity. *Nature*
805   **519**, 97–101 (2015).

806   22. Ewald, C. Y., Castillo-Quan, J. I. & Blackwell, T. K. Untangling Longevity, Dauer, and
807   Healthspan in Caenorhabditis elegans Insulin/IGF-1-Signalling. *Gerontology* **64**, 96–104
808   (2018).

809   23. Gems, D. *et al.* Two pleiotropic classes of daf-2 mutation affect larval arrest, adult
810   behavior, reproduction and longevity in Caenorhabditis elegans. *Genetics* **150**, 129–155
811   (1998).

812   24. Hess, M., Gomariz, A., Goksel, O. & Ewald, C. Y. In-vivo quantitative image analysis of
813   age-related morphological changes of C. elegans neurons reveals a correlation between
814   neurite bending and novel neurite outgrowths. *Eneuro* **6**, ENEURO.0014-19.2019 (2019).

815   25. Leong, D. P. *et al.* Prognostic value of grip strength: findings from the Prospective Urban
816   Rural Epidemiology (PURE) study. *Lancet* **386**, 266–273 (2015).

817   26. Stroustrup, N. *et al.* The Caenorhabditis elegans Lifespan Machine. *Nature Methods* **10**,
818   665–670 (2013).

819   27. Zhang, W. B. *et al.* Extended Twilight among Isogenic C. elegans Causes a
820   Disproportionate Scaling between Lifespan and Health. *Cell Systems* **3**, 333-345.e4 (2016).

821   28. Petrella, J. K., Kim, J., Tuggle, S. C., Hall, S. R. & Bamman, M. M. Age differences in
822   knee extension power, contractile velocity, and fatigability. *J Appl Physiol* **98**, 211–220
823   (2005).

824 29. Kostka, T. Quadriceps maximal power and optimal shortening velocity in 335 men aged
825 23–88 years. *Eur J Appl Physiol* **95**, 140–145 (2005).

826 30. Baasch, T. *et al.* Acoustic Compressibility of Caenorhabditis elegans. *Biophysical journal*
827 **115**, 1817–1825 (2018).

828 31. Donnelly, J. L. *et al.* Monoaminergic Orchestration of Motor Programs in a Complex C.
829 elegans Behavior. *Plos Biol* **11**, e1001529 (2013).

830 32. Hulme, S. E. *et al.* Lifespan-on-a-chip: microfluidic chambers for performing lifelong
831 observation of C. elegans. *Lab on a chip* **10**, 589–597 (2010).

832 33. Shi, C. & Murphy, C. T. Mating induces shrinking and death in Caenorhabditis mothers.
833 *Science (New York, NY)* **343**, 536–540 (2014).

834 34. Ezcurra, M. *et al.* C. elegans Eats Its Own Intestine to Make Yolk Leading to Multiple
835 Senescent Pathologies. *Current biology : CB* **28**, 2544-2556.e5 (2018).

836 35. Gilpin, W., Uppaluri, S. & Brangwynne, C. P. Worms under Pressure: Bulk Mechanical
837 Properties of C. elegans Are Independent of the Cuticle. *Biophysical journal* **108**, 1887–1898
838 (2015).

839 36. Essmann, C. L. *et al.* Mechanical properties measured by atomic force microscopy define
840 health biomarkers in ageing C. elegans. *Nature communications* **11**, 1043 (2020).

841 37. Olshansky, S. J. & Carnes, B. A. Inconvenient Truths About Human Longevity. *The*
842 *journals of gerontology Series A, Biological sciences and medical sciences* **74**, S7–S12
843 (2019).

844 38. Freund, A. Untangling Aging Using Dynamic, Organism-Level Phenotypic Networks.
845 *Cell Systems* **8**, 172–181 (2019).

846 39. Gems, D. The aging-disease false dichotomy: understanding senescence as pathology.
847 *Frontiers in genetics* **6**, 212 (2015).

848 40. Ayyadevara, S., Alla, R., Thaden, J. J. & Reis, R. J. S. Remarkable longevity and stress
849 resistance of nematode PI3K-null mutants. *Aging cell* **7**, 13–22 (2008).

850 41. Stroustrup, N. *et al.* The temporal scaling of Caenorhabditis elegans ageing. *Nature* **530**,
851 103–107 (2016).

852 42. Tarkhov, A. E. *et al.* A universal transcriptomic signature of age reveals the temporal
853 scaling of Caenorhabditis elegans aging trajectories. *Scientific reports* **9**, 7368 (2019).

854 43. Gladyshev, V. N. The origin of aging: imperfectness-driven non-random damage defines
855 the aging process and control of lifespan. *Trends in genetics : TIG* **29**, 506–512 (2013).

856 44. Lippuner, A. D., Julou, T. & Barral, Y. Budding yeast as a model organism to study the
857 effects of age. *FEMS microbiology reviews* **38**, 300–325 (2014).

43

858 45. Yang, Y. *et al.* Temporal scaling of aging as an adaptive strategy of Escherichia coli.
859 *Science advances* **5**, eaaw2069 (2019).

860 46. Kuo, P. L. *et al.* A roadmap to build a phenotypic metric of ageing: insights from the
861 Baltimore Longitudinal Study of Aging. *Journal of Internal Medicine* **287**, 373–394 (2020).

862 47. Ash, A. S. *et al.* Are Members of Long-Lived Families Healthier Than Their Equally
863 Long-Lived Peers? Evidence From the Long Life Family Study. *The journals of gerontology*
864 *Series A, Biological sciences and medical sciences* **70**, 971–976 (2015).

865 48. Sebastiani, P. *et al.* Families Enriched for Exceptional Longevity also have Increased
866 Health-Span: Findings from the Long Life Family Study. *Frontiers in public health* **1**, 38
867 (2013).

868 49. Freedman, V. A., Wolf, D. A. & Spillman, B. C. Disability-Free Life Expectancy Over 30
869 Years: A Growing Female Disadvantage in the US Population. *American journal of public*
870 *health* **106**, 1079–1085 (2016).

871 50. Fischer, K. E. *et al.* A cross-sectional study of male and female C57BL/6Nia mice
872 suggests lifespan and healthspan are not necessarily correlated. *Aging* **8**, 2370–2391 (2016).

873 51. Garcia-Valles, R. *et al.* Life-long spontaneous exercise does not prolong lifespan but
874 improves health span in mice. *Longevity & healthspan* **2**, 14 (2013).

875 52. Mattison, J. A. *et al.* Impact of caloric restriction on health and survival in rhesus
876 monkeys from the NIA study. *Nature* **489**, 318–321 (2012).

877 53. Bellantuono, I. *et al.* A toolbox for the longitudinal assessment of healthspan in aging
878 mice. *Nature Protocols* **15**, 540–574 (2020).

879 54. Collins, J. J., Huang, C., Hughes, S. & Kornfeld, K. The measurement and analysis of
880 age-related changes in Caenorhabditis elegans. *WormBook : the online review of C elegans*
881 *biology* 1–21 (2008) doi:10.1895/wormbook.1.137.1.

882 55. Teuscher, A. C., Statzer, C., Pantasis, S., Bordoli, M. R. & Ewald, C. Y. Assessing
883 Collagen Deposition During Aging in Mammalian Tissue and in Caenorhabditis elegans.
884 *Methods Mol Biology Clifton N J* **1944**, 169–188 (2019).

885 56. Haefke, A. & Ewald, C. Tail Tendon Break Time for the Assessment of Aging and
886 Longitudinal Healthspan in Mice. *Bio-protocol* **10**, (2020).

887 57. Teuscher, A. C. & Ewald, C. Y. Overcoming Autofluorescence to Assess GFP Expression
888 During Normal Physiology and Aging in Caenorhabditis elegans. *BIO-PROTOCOL* **8**, (2018).

889